口服脂质纳米晶两性霉素B治疗隐球菌性脑膜炎:一项随机临床试验
本随机临床试验在人类免疫缺陷病毒相关隐球菌性脑膜炎患者中比较口服脂质纳米晶(LNC)两性霉素B与静脉两性霉素B,共4个序贯队列。口服方案组脑脊液早期杀菌活性为0.40-0.42 log10 CFU/mL/d,静脉对照组为0.46 log10 CFU/mL/d;两组18周生存率相似(85%-90% vs 85%),口服组3-4级实验室不良事件更少(41% vs 61%,P=0.05)。
要点
- 口服LNC两性霉素B组脑脊液早期杀菌活性为0.40-0.42 log10 CFU/mL/d,静脉对照组为0.46 log10 CFU/mL/d。
- 口服LNC两性霉素B组18周生存率为85%-90%,静脉对照组为85%。
- 口服LNC两性霉素B组3-4级实验室不良事件发生率41%,低于静脉对照组的61%(P=0.05)。
核心结论
- 这种新型口服两性霉素B脂质纳米晶(LNC)制剂在隐球菌性脑膜炎中显示出有前景的抗真菌活性、与静脉两性霉素B相似的生存率以及更低的毒性。
研究设计与样本
- 随机临床试验,纳入人类免疫缺陷病毒相关隐球菌性脑膜炎患者,设4个序贯队列:2个预试验队列评估安全性和耐受性(每队列n=10),2个队列评估疗效(有/无2次静脉负荷剂量,每队列n=40)。
- 随机分配80例参与者至口服LNC两性霉素B+氟胞嘧啶组(有静脉负荷剂量n=40,无静脉负荷剂量n=40),41例对照参与者至静脉两性霉素B+氟胞嘧啶组。
- 试验组接受口服LNC两性霉素B 1.8 g/d持续2周联合氟胞嘧啶100 mg/kg/d,随后口服LNC两性霉素B 1.2 g/d持续6周;随机对照组接受静脉两性霉素B联合氟胞嘧啶7天,随后氟康唑1200 mg/d 7天。
- 主要终点为脑脊液早期杀菌活性(EFA)。
主要发现
- 全口服LNC两性霉素B组平均EFA为0.40 log10 CFU/mL/d,口服LNC两性霉素B联合静脉负荷剂量组为0.42 log10 CFU/mL/d,静脉两性霉素B对照组为0.46 log10 CFU/mL/d。
- LNC两性霉素B组2周脑脊液无菌率为63%(44/70),对照组为68%(23/34)。
- 18周生存率:全口服LNC两性霉素B组为85%(34/40),口服LNC两性霉素B联合静脉负荷剂量组为90%(36/40),静脉两性霉素B组为85%(35/41)。
- 3-4级实验室不良事件在LNC两性霉素B组发生率(41%)低于静脉两性霉素B组(61%,P=0.05),尤其是贫血(21% vs 44%;P=0.01)和钾(5% vs 17%;P=0.04)。
临床怎么用
- 作者认为这种新型口服两性霉素B LNC制剂在隐球菌性脑膜炎中显示出有前景的抗真菌活性、与静脉两性霉素B相似的生存率以及更低的毒性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Amphotericin B is the gold standard treatment for severe mycoses. A new orally delivered, less-toxic formulation of amphotericin has been developed. METHODS: In our randomized clinical trial, we tested oral lipid nanocrystal (LNC) amphotericin B (MAT2203, Matinas Biopharma) vs intravenous (IV) amphotericin for human immunodeficiency virus-associated cryptococcal meningitis in 4 sequential cohorts. Two pilot cohorts assessed safety and tolerability (n = 10 each), and 2 cohorts assessed efficacy with/without 2 IV loading doses (n = 40 each). The experimental arm received 1.8 g/d oral LNC amphotericin through 2 weeks with 100 mg/kg/d flucytosine, then 1.2 g/d LNC amphotericin through 6 weeks. The randomized control arm (n = 41) received 7 days of IV amphotericin with flucytosine, then 7 days of fluconazole 1200 mg/d. The primary end point was cerebrospinal fluid (CSF) early fungicidal activity (EFA). RESULTS: We randomized 80 participants to oral LNC amphotericin + flucytosine with (n = 40) and without (n = 40) 2 IV loading doses and 41 control participants to IV amphotericin + flucytosine. Mean EFA was 0.40 log10 colony-forming units (CFU)/mL/d for all-oral LNC amphotericin, 0.42 log10 Cryptococcus CFU/mL/d for oral LNC amphotericin with IV loading doses, and 0.46 log10 CFU/mL/d for IV amphotericin controls. LNC amphotericin groups achieved 2-week CSF sterility in 63% (44 of 70) vs 68% (23 of 34) of controls. The 18-week survival was 85% (34 of 40) with all-oral LNC amphotericin, 90% (36 of 40) with oral LNC amphotericin given IV loading doses, and 85% (35 of 41) with IV amphotericin.Grade 3-4 laboratory adverse events occurred less frequently in LNC amphotericin groups (41%) than the IV amphotericin group (61%, P = .05), particularly for anemia (21% vs 44%; P = .01) and potassium (5% vs 17%; P = .04). CONCLUSIONS: This new oral amphotericin B LNC formulation appears promising for cryptococcal meningitis with antifungal activity, similar survival, and less toxicity than IV amphotericin. CLINICAL TRIALS REGISTRATION: NCT04031833.
引用
- Boulware DR, Atukunda M, Kagimu E, et al. Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial. Clin Infect Dis. 2023. PMID: 37606364. doi:10.1093/cid/ciad440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。